Ono Pharmaceutical Partners with Congruence Therapeutics for Neurology and Immunology Drug Discovery
Ono Pharmaceutical has expanded its collaboration with Congruence Therapeutics, leveraging the Revenir platform to discover small molecule modulators in neurology and immunology. Ono will hold exclusive worldwide option rights for development and commercialisation of resulting candidates.
Congruence Therapeutics | 03/03/2026 | By Akanki | 136
Ono and Congruence to Generate Novel Small Molecule Correctors in Oncology Area
Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, Revenir™.
Congruence Therapeutics | 07/12/2024 | By Aishwarya | 489
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy